Corbus Pharmaceuticals
CRBP
140 hedge funds and large institutions have $383M invested in Corbus Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 42 funds opening new positions, 46 increasing their positions, 27 reducing their positions, and 12 closing their positions.
250% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 12
107% more capital invested
Capital invested by funds: $185M → $383M (+$198M)
98% more call options, than puts
Call options by funds: $49.2M | Put options by funds: $24.8M
70% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 27
26% more funds holding
Funds holding: 111 → 140 (+29)
0.47% more ownership
Funds ownership: 1.62% → 2.1% (+0.47%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Carmignac Gestion
Paris,
France
|
+$20.5M |
| 2 |
State Street
Boston,
Massachusetts
|
+$12.7M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$10.1M |
| 4 |
D.E. Shaw & Co
New York
|
+$5.57M |
| 5 |
Morgan Stanley
New York
|
+$3.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$4.31M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$1.84M |
| 3 |
JP Morgan Chase
New York
|
-$1.43M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.12M |
| 5 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
-$849K |
CRBP Hedge Fund Activity: Q2 2020 in Review
140 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q2 2020, worth a combined $383M — up 107% from $185M a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new CRBP positions and 12 closed out — a net gain of 30 holders — while 46 added to existing stakes and 27 trimmed.
The largest buyer was Carmignac Gestion, adding an estimated $20.5M. The largest seller was DAFNA Capital Management, cutting an estimated $4.31M.
- 140 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q2 2020, up from 111 in Q1 2020.
- Funds reported $383M of Corbus Pharmaceuticals stock for Q2 2020, up 107% quarter-over-quarter.
- 42 funds opened new Corbus Pharmaceuticals positions in Q2 2020 and 12 closed out, a net change of +30 holders.
- The largest Corbus Pharmaceuticals buyer in Q2 2020 was Carmignac Gestion, an estimated $20.5M added.
- The largest Corbus Pharmaceuticals seller in Q2 2020 was DAFNA Capital Management, an estimated $4.31M sold.
Based on aggregated 13F filings for Q2 2020.